Live Chat

CFD:er är komplexa instrument som innebär hög risk att du förlorar pengar snabbt på grund av hävstången. 74% av icke-professionella investerares konton förlorar pengar när de handlar med CFD:er hos den här leverantören. Du bör överväga om du förstår hur CFD:er fungerar och om du har råd att ta den höga risken att förlora dina pengar.

Close

Affär Amgen AMGN

Amgen realtidsdiagram

Instrumentfundament

Weekly Search
Weekly
Daily
Datum Stäng Förändring Förändring (%) Öppna Hög Låg

Senaste nyheter

Global finance
Neil Wilson 2024 Nov 14, 17:00

Fed Hints at Tight Policy Amid Global Economic Uncertainty

Fed
Frances Wang 2024 Nov 14, 16:00

Dogecoin surges after Elon Musk issues crypto endorsement

Cryptocurrencies
Nvidia Blackwell AI Chips
Neil Wilson 2024 Nov 14, 16:00

Week ahead: Tech rally hinges on Nvidia earnings

Forex Indices
Frances Wang 2024 Nov 14, 16:00

Stock Market Today: Indexes Drop as Fed Rate Cuts are still underway

Fed Stocks
Frances Wang 2024 Nov 14, 16:00

What's Going On With Amazon Stock today? Is AMZN expected to rise?

Stocks AMZN
Dogecoin surges
Neil Wilson 2024 Nov 13, 17:00

Dogecoin surges as Trump unveils new government efficiency initiative with Musk andRamaswamy

Cryptocurrencies
Frances Wang 2024 Nov 13, 16:00

Japanese Yen to USD: Yen drops to fresh multi-month low against USD

Forex
Frances Wang 2024 Nov 13, 16:00

Asia markets today: Nikkei 225 up 0.18%, Hang Seng Index falls by 197 points

Indices

Info

Spread

1.98

Spread (%)

0.7007 %

Hävstångseffekt

1:5

Köp till dagslåneränta

-0.0597 %

Sälj till dagslåneränta

-0.0292 %

Valuta

USD

Handelstider

Marknaden är öppen

Fredag

14:31 - 20:59

Måndag

14:31-20:59

Tisdag

14:31-20:59

Onsdag

14:31-20:59

Torsdag

14:31-20:59

Analys och statistik

Öppna

---

Föregående stängning

---

52 veckors högsta/lägsta

--- – ---

Marknadsvärde

159072141312

Utelöpande aktier

537532992

Rapportdatum (nästa)

1999-11-22

Utd-procent

2024-12-09

Datum efter utdelning

2024-11-18

Förväntad framtida årlig utdelningsprocent

9

Förväntad framtida årlig direktavkastning

0.0304

Vinst per aktie

7.84

Läs mer om detta instrument

Amgen Amgen Inc
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Läs mer om detta instrument

Tillgång
Sälj
Köp
Förändring (%)
Relaterade instrument
Trustpilot
Live Chat